https://csimarket.com/rss/news.php News about Medical Research and results of clinical trials - CSIMarket.com en-us Copyright (C) 2026 csimarket.com https://csimarket.com/news/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-ant2025-11-27142534https://csimarket.com/news/news.php?date=2025-11-27142534 $CELC Advancements in Targeted Oncology: An Overview of Celcuity's Latest Findings and Future Directions Breast cancer remains one of the most prevalent and challenging malignancies to treat, requiring continuous efforts in research and development of new therapeutic strategies. Celcuity Inc., a clinical-stage biotechnology company, has positioned itself at the forefront of these efforts. Their pioneering work on targeted therapies offers promising avenues for managing advanced breast cancer, particularly through innovations in addressing the PIK3CA wild-type cohort and combining therapeutic agents. This article synthesizes findings from recent studies and conference presentations pivotal to the advancements in breast cancer therapeutics. PIK3CA Wild-Type Cohort: VIKTORIA-1 Trial Insights Celcuity's announcement regarding the presentation of updated data from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial at the 2025 San Antonio Breast Cancer Symposium (SABCS) underscores a significant milestone. This trial investigates the efficacy of targeted therapies in patients who do not have P Thu, 27 Nov 2025 14:25:34 +0000article@csimarket.com (Contact Csimarket) https://csimarket.com/news/hutchmed-to-showcase-innovative-clinical-findings-at-the-2025-esmo-asia-congress-and-ash-annual-meeting2025-11-27141328https://csimarket.com/news/news.php?date=2025-11-27141328 $HCM In a notable advancement for the oncology and hematology communities, HUTCHMED (China) Limited has announced that it will unveil new and updated clinical data at two prominent international meetings''the European Society for Medical Oncology (ESMO) Asia Congress 2025 and the American Society of Hematology (ASH) Annual Meeting. These presentations, scheduled to take place consecutively from December 5-9, 2025, in Singapore and Orlando, respectively, are poised to highlight HUTCHMED's commitment to advancing cancer therapeutics and hematological research through innovative compounds. The ESMO Asia Congress, a pivotal forum for oncologists across the Asia-Pacific region, will serve as the backdrop for the unveiling of findings related to HUTCHMED's proprietary compounds. These data presentations are expected to cover a spectrum of clinical studies. Each study not only reflects the company's robust research pipeline but also underscores its dedication to providing nov Thu, 27 Nov 2025 14:13:28 +0000article@csimarket.com (Contact Csimarket) https://csimarket.com/news/eyepoint-pharmaceuticals-advances-duravyu-trials-a-promising-leap-towards-new-treatments-for-vision-loss-br2025-11-19122643https://csimarket.com/news/news.php?date=2025-11-19122643 $EYPT In a significant boost for the field of ophthalmology, EyePoint Pharmaceuticals has announced a positive recommendation from the Independent Data Safety Monitoring Committee (DSMC) regarding its pivotal Phase 3 trials for DURAVYU, specifically targeting the treatment of wet age-related macular degeneration (wet AMD). The favorable review was provided for two ongoing clinical trials, LUGANO and LUCIA, reaffirming the safety and efficacy of the treatment, with no protocol changes recommended. This is a triumphant milestone for the company and its vision of advancing cutting-edge therapies for this debilitating condition. Progress in Clinical Trials The ongoing LUGANO and LUCIA trials are part of EyePoint's essential Phase 3 pivotal program aimed at securing regulatory approval for DURAVYU. Notably, it was revealed that the first patient has been dosed in the LUCIA trial, underscoring the rapid progression of their clinical efforts. As EyePoint Pharmaceuticals has indicated, topline data for this pivotal program is anticipated to be available in 2026, potentially paving the way for a novel Wed, 19 Nov 2025 12:26:43 +0000article@csimarket.com (Contact Csimarket) https://csimarket.com/news/breakthrough-in-autoimmune-therapy-cartesian-therapeutics-shines-with-descartes-08-in-sle-and-myasthenia-gravis-trials2025-11-14095420https://csimarket.com/news/news.php?date=2025-11-14095420 $RNAC A New Dawn for Autoimmune Diseases: Cartesian Therapeutics' Descartes-08 Shows Promising Results in SLE and Myasthenia Gravis In a landscape where autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis pose significant challenges to patients and clinicians alike, Cartesian Therapeutics is making impressive strides with its mRNA cell therapy, Descartes-08. Recent reports from the company's Phase 2 trials have highlighted a strong efficacy signal, indicating a potential paradigm shift in therapeutic approaches for these debilitating conditions. Efficacy Signals in SLE In a Phase 2 open-label trial tracking three patients with SLE, Cartesian Therapeutics reported a remarkable 100% LLDAS (Low Disease Activity State) response rate at the three-month follow-up. This outcome not only underlines the potential of Descartes-08 as a viable treatment option but also reinforces the therapeutic promise of mRNA technology in managing complex autoimmune disorders. The drug's efficacy in this early-stage trial serves as a precursor for Cartesian's ambitious plans to expand the c Fri, 14 Nov 2025 09:54:20 +0000article@csimarket.com (Contact Csimarket) https://csimarket.com/news/promising-advances-in-mcrpc-treatment-insights-from-oric-944-phase-1b-trials2025-11-14095220https://csimarket.com/news/news.php?date=2025-11-14095220 $ORIC The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) continues to challenge clinicians due to inherent and acquired therapeutic resistance. In recent developments, ORIC Pharmaceuticals has reported promising results from its ongoing Phase 1b clinical trial evaluating ORIC-944, an innovative, experimental therapy designed to overcome therapeutic resistance mechanisms in mCRPC. Emerging data highlight the drug's potential efficacy and safety, positioning ORIC-944 as a potentially best-in-class treatment option. mCRPC represents a critical stage in prostate cancer progression, often characterized by resistance to existing therapies, including androgen receptor (AR) inhibitors. Identifying therapies that can effectively overcome this resistance is a significant focus for oncology research and development. ORIC Pharmaceuticals, a leader in this domain, is advancing ORIC-944, a treatment candidate designed to modulate therapeutic resistance mechanisms uniquely. 'Study Overview:' In a recent announcement, ORIC Pharmaceuticals concluded the dose exploration portion of its Phase 1b clinical trial for ORIC-944. The trial investigates t Fri, 14 Nov 2025 09:52:20 +0000article@csimarket.com (Contact Csimarket)